 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Fasinex, Egaten, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619048 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Oxidation to sulfone and sulfoxide metabolites |
| Eliminationhalf-life | 22–24 hours |
| Excretion | Feces (>95%), urine (2%), milk (<1%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.127.414 |
| Chemical and physical data | |
| Formula | C14H9Cl3N2OS |
| Molar mass | 359.65 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 175 to 176 °C (347 to 349 °F) |
| |
| |
 N Y (what is this?) (verify) | |
Triclabendazole, sold under the brand nameEgaten among others, is a medication used to treatfascioliasis andparagonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]
Side effects are generally few, but can include abdominal pain and headaches.[1]Biliary colic may occur due to dying worms.[2] While no harm has been found with use duringpregnancy, triclabendazole has not been studied well in this population.[2] It is a member of thebenzimidazole family ofmedications for worms.[1]
Triclabendazole was approved for medical use in the United States in 2019.[3][4] It is on theWorld Health Organization's List of Essential Medicines.[5] For human use, it can be obtained from the World Health Organization.[2] It is also used in animals.[6]
It is a member of thebenzimidazole family ofanthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but nocarbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind tobeta-tubulin therefore preventing the polymerization ofmicrotubules.[7]
Since late 1990s, triclabendazole became available as ageneric drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% andivermectin 0.6% solution, is designed to treat infections byFasciola hepatica (both immature and adultliver flukes),roundworms and ectoparasites, as well.[citation needed]
Fasinex is a brand name for veterinary use while Egaten is a brand name for human use.[citation needed]
